We are live on ! Find out more
ATNM icon

Actinium Pharmaceuticals

43 hedge funds and large institutions have $4.16M invested in Actinium Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

2% more funds holding

Funds holding: 42 → 43 (+1)

6% more capital inflows, than outflows

Capital inflows: $858K | Capital outflows: $810K

0.21% less ownership

Funds ownership: 7.48% → 7.27% (-0.21%)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

40% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 10

Holders
43
Holders Change
+1
Holders Change %
+2.38%
% of All Funds
0.93%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
6
Reduced
10
Closed
6
Calls
$78​K
Puts
–
Net Calls
+$78​K
Net Calls Change
-⁠$13​K

ATNM Hedge Fund Activity: Q1 2019 in Review

43 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q1 2019, worth a combined $4.16M — up 24% from $3.36M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of ATNM and 5 opened new positions — a net loss of 1 holder — while 10 trimmed existing stakes and 6 added.

The largest buyer was Vanguard Group, adding an estimated $651K. The largest seller was DLD Asset Management, cutting an estimated $624K.

  • 43 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q1 2019, up from 42 in Q4 2018.
  • Funds reported $4.16M of Actinium Pharmaceuticals stock for Q1 2019, up 24% quarter-over-quarter.
  • 5 funds opened new Actinium Pharmaceuticals positions in Q1 2019 and 6 closed out, a net change of -1 holder.
  • The largest Actinium Pharmaceuticals buyer in Q1 2019 was Vanguard Group, an estimated $651K added.
  • The largest Actinium Pharmaceuticals seller in Q1 2019 was DLD Asset Management, an estimated $624K sold.

Based on aggregated 13F filings for Q1 2019.